DNLI
$20.17+0.42 (+2.13%)
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Recent News
Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial Readouts
Denali Therapeutics (NASDAQ:DNLI) founder and CEO Ryan Watts said 2026 is shaping up to be a pivotal year for the company as it approaches a potential first product approval and advances multiple transport vehicle-enabled programs across rare disease and neurodegeneration. Speaking in a moderated d
Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts Build
Denali Therapeutics (NASDAQ:DNLI) executives outlined near-term regulatory milestones, commercial launch preparations, and a broadening pipeline during a discussion hosted by Leerink Partners analyst Marc Goodman. Chief Executive Officer Ryan Watts and Chief Commercial Officer Katie Peng focused on
Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed?
Earlier in March 2026, Denali Therapeutics Inc. presented at the UBS Biotech Summit and Jefferies Biotech on the Beach Summit in Miami, highlighting its rare disease programs and blood–brain barrier platform. Investor attention is increasingly centered on tividenofusp alfa for Hunter syndrome, with an upcoming FDA action date viewed as a key test of Denali’s therapeutic approach. We’ll now examine how anticipation around the FDA decision on tividenofusp alfa could influence Denali’s...
Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price Gains
Denali Therapeutics (DNLI) has been drawing attention after recent share price moves, with the stock up 27.2% year to date and delivering a 39% total return over the past year. This performance has prompted fresh investor scrutiny. See our latest analysis for Denali Therapeutics. The recent 7 day share price return of 5.1% and 90 day share price return of 15.1%, against a 1 year total shareholder return of 39%, point to momentum that has picked up in the short term after a weaker multi year...
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.